Trial Profile
A Prospective, Randomized, Factorial Design, Interventional Study to Compare the Safety and Efficacy of Combinations of Blockade of Interleukin-6 Pathway and Interleukin-1 Pathway to Best Standard of Care in Improving Oxygenation and Short- and Long-term Outcome of COVID-19 Patients With Acute Hypoxic Respiratory Failure and Systemic Cytokine Release Syndrome
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 16 Mar 2023
Price :
$35
*
At a glance
- Drugs Anakinra (Primary) ; Siltuximab (Primary) ; Tocilizumab (Primary)
- Indications Acute hypoxia; COVID 2019 infections; Cytokine release syndrome; Respiratory insufficiency; SARS-CoV-2 acute respiratory disease
- Focus Therapeutic Use
- Acronyms COV-AID
- 15 Jul 2021 Status changed from active, no longer recruiting to completed.
- 01 Mar 2021 Planned End Date changed from 1 Mar 2021 to 12 Apr 2021.
- 14 Dec 2020 For Hypoxic-respiratory-failure and respiratory-insufficiency narrower term is ARDS, so I have added ARDS.